FNY Managed Accounts’s Antares Pharma, Inc. ATRS Stock Holding History

FNY Managed Accounts’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-800	Closed	-$2K	–	882
2017 Q3	$2K	Buy	+800	New	+$2.47K	﹤0.01%	583
2015 Q3	–	Sell	-7,000	Closed	-$14.6K	–	614
2015 Q2	$14.6K	Sell	7,000 -83,000	-92%	-$201K	0.02%	291
2015 Q1	$244K	Buy	+90,000	New	+$228K	0.2%	66

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FNY Managed Accounts's ATRS Position: Q4 2017 in Review

FNY Managed Accounts sold out of Antares Pharma, Inc. (ATRS) in Q4 2017, closing a stake of 800 shares — an estimated $2K sold.

FNY Managed Accounts first reported a position in ATRS in Q1 2015 and held it in 3 quarters. The position peaked at $244K in Q1 2015. 110 funds tracked by Wall St. Rank hold ATRS as of Q4 2017.

FNY Managed Accounts reported no remaining Antares Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
FNY Managed Accounts sold 800 Antares Pharma, Inc. shares in Q4 2017, an estimated $2K.
FNY Managed Accounts first reported a position in Antares Pharma, Inc. in Q1 2015 and held it in 3 quarters.
FNY Managed Accounts's Antares Pharma, Inc. position peaked at $244K in Q1 2015.
110 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2017.

Based on FNY Managed Accounts's 13F filing for Q4 2017, filed 23 Jan 2018.